A jury ordered Takeda Pharmaceutical to pay more than $2 million to a Pennsylvania woman who blamed the Type 2 diabetes drug Actos for causing her bladder cancer. Eight of the nine jurors in Philadelphia state court sided with plaintiff Frances Wisniewski and awarded her $2,050,000. The jury reached its decision after five hours of deliberations, finding that Takeda failed to warn Wisniewski and her doctors about the risk carried by Actos of causing bladder cancer. Jurors also agreed that the Japan-based company did not include enough information on medication labels. "I think the jury was very fair," Michael Miller, Wisniewski's attorney told Law360. "The defendants clearly failed to warn and it clearly caused her damage. She’s got a life of bladder cancer because of it. It’s a fair verdict." The verdict follows a $9 billion courtroom loss the pharmaceutical company took earlier this year for another Actos bladder cancer case, the largest verdict to date related to Actos. That verdict is under appeal. Actos, released in 1999, made billions for Takeda and at the height of its sales in 2011 reaped an incredible $4.5 billion in a single year. The Type 2 diabetes drug made up over a quarter of the company's profits despite concerns of heart failure, liver and kidney disease. Takeda stands by its billion dollar drug, saying it did not cause Wisniewski's bladder cancer. The company plans to challenge the verdict. "We have empathy for Ms. Wisniewski but we believe we presented sufficient evidence to show that her condition was not caused by Actos," Takeda Pharmaceutical USA Senior Vice President and General Counsel Kenneth Greisman said in a statement to The Pharma Letter.
Find Out If You Qualify
Sign up for the latest news and updates from Drugwatch.com and be among the first to know about new safety information:
You will now receive updates from Drugwatch.